Safety and Tolerability Study of Oral NS-018 in Patients... | NCT01423851 | Trialant
NCT01423851
Sponsor
NS Pharma, Inc.
Status
Completed
Last Update Posted
Mar 9, 2022Actual
Enrollment
77Actual
Phase
Phase 1Phase 2
Conditions
Primary Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
Post-Essential Thrombocythemia Myelofibrosis
Interventions
NS-018
Countries
United States
Protocol Section
Identification Module
NCT ID
NCT01423851
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
NS-018-101
Secondary IDs
Not provided
Brief Title
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Official Title
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Acronym
Not provided
Organization
NS Pharma, Inc.INDUSTRY
Status Module
Record Verification Date
Feb 2022
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Jun 2011
Primary Completion Date
Apr 22, 2020Actual
Completion Date
Apr 22, 2020Actual
First Submitted Date
Aug 15, 2011
First Submission Date that Met QC Criteria
Aug 25, 2011
First Posted Date
Aug 26, 2011Estimated
Results Waived
Not provided
Results First Submitted Date
Nov 12, 2021
Results First Submitted that Met QC Criteria
Feb 10, 2022
Results First Posted Date
Mar 9, 2022Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Sep 10, 2021
Certification/Extension First Submitted that Passed QC Review
Sep 10, 2021
Certification/Extension First Posted Date
Sep 14, 2021Actual
Last Update Submitted Date
Feb 10, 2022
Last Update Posted Date
Mar 9, 2022Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
NS Pharma, Inc.INDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
Yes
Is FDA Regulated Drug
Not provided
Is FDA Regulated Device
Not provided
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (post-ET MF)
Detailed Description
This is a Phase 1/2 study that is currently enrolling Janus kinase 2 (JAK2) failures into the Phase 2 portion of the study.
Conditions Module
Conditions
Primary Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
Post-Essential Thrombocythemia Myelofibrosis
Keywords
Keywords provided by NS Pharma, Inc.:
JAK2 kinase inhibitor
NS-018
Myeloproliferative Neoplasms
Primary Myelofibrosis
post-Polycythemia Vera Myelofibrosis
post-Essential Thrombocythemia Myelofibrosis
Additional relevant MeSH terms:
Bone Marrow Diseases
Hematologic Diseases
Polycythemia Vera
Thrombocythemia, Essential
PMF
post-PV MF
post-ET MF
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 1Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
77Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Intervention: Drug: NS-018
Experimental
In Phase 1 part, subjects were treated with oral NS-018 at a dose of 75 - 400 mg once daily or 100 - 400 mg twice daily. In Phase 2 part, subjects were treated with oral NS-018 at a dose of 300 mg once daily.
Drug: NS-018
Interventions
Name
Type
Description
Arm Group Labels
Other Names
NS-018
Drug
Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).
Intervention: Drug: NS-018
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event
AEs (non-serious, serious) as variables of safety and tolerability of NS-018 were assesed. The number of patients were presented as Overall summary of AEs including treatment-emergent AEs (TEAEs); Treatment-emergent SAEs; Drug-related TEAEs; Treatment-emergent AEs leading to permanent discontinuation of study drug; Hospitalization or prolongation of existing hospitalization; Death.
From screening to until study discontinuation (approximate 8 years 10 months)
Part 2: Number of Patient With Objective Response Using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Leukemia Net (ELN)
Six response categories are listed: complete remission (CR) and partial remission signify treatment effects that are consistent with disease modification, whereas drug-induced improvements in MF-symptomatic burden were annotated as clinical improvement, anemia response, spleen response, orsymptoms response. Additional criteria are provided for progressive disease, stable disease, and relapse. The objective response was defined as the number of patients with confirmed complete remission (CR) + partial response (PR) + clinical improvement (CI) during the treatment period.
Cycle 7 Day 1 (duration of cycle was 4 weeks)
Part 2: Change From Baseline in Spleen Size
Change from baseline in spleen size was assessed by magnetic resonance imaging (MRI) (computed tomography [CT] scan for patients not able to tolerate MRI).
From Baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
Part 2: Change From Baseline in Bone Marrow Assessment
Bone marrow was assessed by aspiration and biopsy for grade changes in osteomyelofibrosis. Fibrosis was graded according to European Consensus Myelofibrosis Grading Criteria, ranging from grade 0, which corresponds to normal bone marrow, to grade 3, in which coarse bundles of collagen fibrosis are identifiable with significant osteosclerosis.
Secondary Outcomes
Measure
Description
Time Frame
Part 1: Number of Patients With Objective Response Using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
Six response categories are listed: complete remission (CR) and partial remission signify treatment effects that are consistent with disease modification, whereas drug-induced improvements in MF-symptomatic burden were annotated as clinical improvement, anemia response, spleen response, orsymptoms response. Additional criteria are provided for progressive disease, stable disease, and relapse. The objective response was defined as the number of patients with confirmed "complete remission (CR) + partial response (PR) + clinical improvement (CI)" during the treatment period.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Primary myelofibrosis, post-PV MF, or post-ET MF that requires therapy
MF patients must have received prior JAK2 inhibitor therapy, and been found to be intolerant, or refractory/relapsed from prior JAK2 inhibitor therapy, based on investigator assessment
≥18 years old
ECOG Performance Status of ≤ 3
Estimated life expectancy of ≥12 weeks
Male or non-pregnant, non-lactating female patients
Serum creatinine of ≤1.5 × the upper limit of normal (ULN)OR estimated creatinine clearance (CrCl) ≥ 40 ml/min/1.73 m2
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × the upper limit of normal (ULN) and total bilirubin ≤1.5 × ULN. If the total bilirubin is elevated between 1.5 x and 3 x ULN, patients with a direct bilirubin ≤ 1.5 X ULN are eligible during the Phase II portion.
Absolute neutrophil count (ANC) >1000/μL and Platelet count > 25,000/μL
QTcB ≤ 480 msec
No MF-directed treatment for at least 2 weeks prior to initiation of NS-018, including any use of corticosteroids for Myelofibrosis symptom or blood count management. Low dose corticosteroids ≤ 10 mg/day prednisone or equivalent is allowed for non-myelofibrosis purposes.
Exclusion Criteria:
Active, uncontrolled systemic infection
Patients with any unresolved toxicity greater than Grade 1 from previous anticancer therapy
Potentially curative therapy is available
Currently taking medication that is substantially metabolized by cytochrome P450 (CYP) 1A2 or CYP3A4 or taking medication known to be strong inhibitors or inducers of CYP3A4
Patients with a serious cardiac condition within the past 6 months
Pregnant or lactating
Radiation therapy for splenomegaly within 6 months prior to study entry
Splenectomy (Phase 2 portion of the study only)
Known HIV positive status
Known active hepatitis, a history of viral hepatitis B or hepatitis C
Verstovsek S, Talpaz M, Ritchie E, Wadleigh M, Odenike O, Jamieson C, Stein B, Uno T, Mesa RA. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2017 Feb;31(2):393-402. doi: 10.1038/leu.2016.215. Epub 2016 Aug 1.
See Also Links
Not provided
Available IPD Information
Not provided
IPD Sharing Statement Module
No data available
No data is available for this block.
Results Section
Participant Flow Module
Pre-assignment Details
The screening period was from Day -14 to Day 0 for Phase I and Phase II. Informed consent form (ICF) was signed prior to screening procedures. All the study assessments were performed as per the schedule of assessment.
Recruitment Details
Subjects who met all the inclusion and none of the exclusion criteria were enrolled at 09 sites in the USA. The conduct of this study started on 02 June 2011 (the first patient screened) and the last patient last visit was on 22 April 2020.
A total of 48 and 29 patients were enrolled during Phase 1 and Phase 2 of the study respectively.
Participants could be reduced or escalated to the noted dose at physician discretion.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
Cycle 7 Day 1 (duration of cycle was 4 weeks)
Part 1: Change From Baseline in Spleen Size
Change from baseline in spleen size was assessed by palpation.
From Baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
Part 1: Change From Baseline in Bone Marrow Assessment
Bone marrow was assessed by aspiration and biopsy for grade changes in osteomyelofibrosis. Fibrosis was graded according to European Consensus Myelofibrosis Grading Criteria, ranging from grade 0, which corresponds to normal bone marrow, to grade 3, in which coarse bundles of collagen fibrosis are identifiable with significant osteosclerosis.
From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
Part 1: Change From Baseline in Quality of Life Assessments Using Myelofibrosis Symptom Assessment Form (MF-SAF)
MF SAF is a 20-item instrument comprised of 4 subscales: 1) the Brief Fatigue Inventory [= average of 9 fatigue scores], 2) Splenomegaly associated symptoms [= average of 4 splenomegaly and associated scores], 3) Catabolic/proliferative Symptoms [= average of 3 catabolic/proliferative associated scores] and 4) Overall Quality of Life. The items were on a scale from 1 to 10 where 1= most favorable, and 10= least favorable.
From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
Part 2: Change From Baseline in Quality of Life Assessments Using Myeloproliferative Neoplasm Symptom Assessment Form (MPN SAF (MPN 10)
Symptoms are evaluated by the MPN-SAF Total Symptom Score (TSS). The MPN-SAF TSS is assessed by the patients themselves and this includes fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Scoring is from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be) for each item. The MPN-SAF TSS is the summation of all the individual scores (0-100 scale). Symptoms response requires >50% reduction in the MPN-SAF TSS.
From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
Part 1 and Part 2: Change in Baseline in Janus Kinase 2 (JAK2) V617F Allele Burden Levels
The JAK2 V617F allele burden mean changes from baseline (%) are presented as pharmacodynamics parameters.
Part 1 and Part 2: From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
Part 2: Change From Baseline in Phosphorylated Signal Transducer and Activator of Transcription 3 (Phospho-STAT3)
The Phospho-STAT3 mean changes from baseline (%) are presented as pharmacodynamics parameters.
For phospho-STAT3 values (Phase 2 only), study samples were incubated (± IL-6) and labeled with CD markers. Surface markers included CD3+ (CD4+ [helper T cells] and CD8+ [cytotoxic T cells]) and CD14+ (monocytes) to which intracellular phospho STAT3 was targeted. The levels of phospho-STAT3 in CD14+, CD3+CD4+ and CD3+CD8+ cell subtypes were quantified. Phosphorylated-STAT3 levels were evaluated in the cell types before and after IL-6 incubation (stimulation) and reported both as mean fluorescence intensity (MFI) and the percentage of positive cells. For each sample time point, the MFI was normalized to a fold change.
The fold change was calculated by MFI after IL-6 treatment/MFI before IL-6 treatment. The percent positive cells were normalized by subtracting the percent positive cells before IL-6 treatment from the percent positive cells after IL-6 treatment.
From Baseline to Pre-dose at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 (duration of cycle was 4 weeks)
Part1 and Part 2: Observed Maximum Concentration (Cmax)
To determine the Cmax as pharmacokinetic parameters of NS-018.
Pre-dose, 0.5 to 24 hours post-dose for Part 1: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1 and for Part 2: Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 (duration of cycle was 4 weeks)
Part 1 and Part 2: Time to Maximum Plasma Concentration (Tmax)
To determine the Tmax as pharmacokinetic parameters of NS-018.
Pre-dose, 0.5 to 24 hours post-dose for Part 1: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1 and for Part 2: Cycle 1 Day 1, Cycle 2 Day 1 (duration of cycle was 4 weeks)
Part1 and Part 2: Area Under the Plasma Concentration-time Curve (AUC0-24)
To determine the AUC0-24 as pharmacokinetic parameters of NS-018.
Pre-dose, 0.5 to 24 hours post-dose for Part 1: Cycle 1 Day 1, Cycle 2 Day 1 and for Part 2: Cycle 1 Day 1 (duration of cycle was 4 weeks)
Part 1 and Part 2: Terminal Elimination Half-life (t½)
To determine the t½ as pharmacokinetic parameters of NS-018.
Pre-dose, 0.5 to 24 hours post-dose for Part 1: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1 and for Part 2: Cycle 1 Day 1, Cycle 2 Day 1 (duration of cycle was 4 weeks)
Part1 and Part 2: Accumulation Ratio (AR)
To determine the AR as pharmacokinetic parameters of NS-018. AR was calculated as AR = (AUC0-24) Cycle 2 Day 1/ (AUC0-24) Cycle 1 Day 1.
Part 1 and Part 2: Cycle 2 Day 1 (duration of cycle was 4 weeks)
San Diego
California
92093-0698
United States
Mayo Clinic, Jacksonville
Jacksonville
Florida
32224
United States
Northwestern University
Chicago
Illinois
60611
United States
University of Chicago
Chicago
Illinois
60637
United States
Dana Farber Cancer Institute
Boston
Massachusetts
02115
United States
University of Michigan
Ann Arbor
Michigan
48109
United States
Weill Cornell Medical College
New York
New York
10021
United States
MD Anderson Cancer Center, Department of Leukemia
Houston
Texas
77030
United States
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
FG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
FG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
FG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
FG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
FG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
FG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
FG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
FG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
FG010
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
FG0003 subjects
FG0013 subjects
FG0023 subjects
FG0036 subjects
FG0043 subjects
FG0053 subjects
FG0063 subjects
FG0078 subjects
FG0088 subjects
FG0098 subjects
FG01029 subjects
COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
NOT COMPLETED
FG0003 subjects
FG0013 subjects
FG0023 subjects
FG0036 subjects
FG0043 subjects
FG0053 subjects
FG0063 subjects
FG0078 subjects
FG0088 subjects
FG0098 subjects
FG01029 subjects
Type
Comment
Reasons
Disease progression
FG0002 subjects
FG0011 subjects
FG0021 subjects
FG0034 subjects
FG0041 subjects
FG0053 subjects
FG0061 subjects
FG0074 subjects
FG0080 subjects
FG0092 subjects
FG01010 subjects
Physician Decision
FG0000 subjects
FG0011 subjects
FG0022 subjects
FG0030 subjects
FG004
Withdrawal by Subject
FG0001 subjects
FG0011 subjects
FG0020 subjects
FG0030 subjects
FG004
Adverse Event
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0032 subjects
FG004
Dose Finding Period - Escalation
Type
Comment
Milestone Data
STARTED
FG0000 subjects
FG0011 subjects
FG0024 subjects
FG0034 subjects
FG0040 subjects
FG0050 subjects
FG0062 subjects
FG0070 subjects
FG0081 subjects
FG0090 subjects
FG0100 subjects
COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
NOT COMPLETED
FG0000 subjects
FG0011 subjects
FG0024 subjects
FG0034 subjects
FG004
Dose Finding Period - Reduction
Type
Comment
Milestone Data
STARTED
FG0000 subjects
FG0010 subjects
FG0023 subjects
FG0035 subjects
FG0041 subjects
FG0052 subjects
FG0068 subjects
FG0070 subjects
FG0083 subjects
FG0090 subjects
FG0100 subjects
COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
NOT COMPLETED
FG0000 subjects
FG0010 subjects
FG0023 subjects
FG0035 subjects
FG004
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
BG001
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
BG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
BG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
BG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
BG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
BG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
BG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
BG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
BG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
BG010
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
BG011
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG0003
BG0013
BG0023
BG0036
BG0043
BG0053
BG0063
BG0078
BG0088
BG0098
BG01029
BG01177
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
Mean
Standard Deviation
Years
Title
Denominators
Categories
Part 1
ParticipantsBG0003
ParticipantsBG0013
ParticipantsBG0023
ParticipantsBG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
ParticipantsBG0003
ParticipantsBG0013
ParticipantsBG002
Race/Ethnicity, Customized
Count of Participants
Participants
Title
Denominators
Categories
White/Caucasian
ParticipantsBG0003
ParticipantsBG0013
ParticipantsBG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event
AEs (non-serious, serious) as variables of safety and tolerability of NS-018 were assesed. The number of patients were presented as Overall summary of AEs including treatment-emergent AEs (TEAEs); Treatment-emergent SAEs; Drug-related TEAEs; Treatment-emergent AEs leading to permanent discontinuation of study drug; Hospitalization or prolongation of existing hospitalization; Death.
The safety population included all patients who received at least 1 dose of study drug.
NS-018-101 study was dose-finding study, Principal investigator (PI) could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
Posted
Count of Participants
Participants
From screening to until study discontinuation (approximate 8 years 10 months)
ID
Title
Description
OG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG001
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG010
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG0003
OG0014
OG00210
OG003
Title
Denominators
Categories
Not TEAE
Title
Measurements
OG0000
OG0010
OG0020
OG003
Primary
Part 2: Number of Patient With Objective Response Using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Leukemia Net (ELN)
Six response categories are listed: complete remission (CR) and partial remission signify treatment effects that are consistent with disease modification, whereas drug-induced improvements in MF-symptomatic burden were annotated as clinical improvement, anemia response, spleen response, orsymptoms response. Additional criteria are provided for progressive disease, stable disease, and relapse. The objective response was defined as the number of patients with confirmed complete remission (CR) + partial response (PR) + clinical improvement (CI) during the treatment period.
The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. Here, the overall number of subjects analyzed signifies only the subjects with available data that were analyzed evaluated on that specific cycle day.
Posted
Count of Participants
Participants
Cycle 7 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Primary
Part 2: Change From Baseline in Spleen Size
Change from baseline in spleen size was assessed by magnetic resonance imaging (MRI) (computed tomography [CT] scan for patients not able to tolerate MRI).
The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. Here, the overall number of subjects analyzed signifies only the subjects with available data that were analyzed evaluated on that specific cycle day.
Posted
Mean
Standard Deviation
cubic millimeter (mm3)
From Baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG000
Primary
Part 2: Change From Baseline in Bone Marrow Assessment
Bone marrow was assessed by aspiration and biopsy for grade changes in osteomyelofibrosis. Fibrosis was graded according to European Consensus Myelofibrosis Grading Criteria, ranging from grade 0, which corresponds to normal bone marrow, to grade 3, in which coarse bundles of collagen fibrosis are identifiable with significant osteosclerosis.
The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. Here, the overall number of subjects analyzed signifies only the subjects with available data that were analyzed evaluated on that specific cycle day.
Posted
Count of Participants
Participants
From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
Secondary
Part 1: Number of Patients With Objective Response Using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
Six response categories are listed: complete remission (CR) and partial remission signify treatment effects that are consistent with disease modification, whereas drug-induced improvements in MF-symptomatic burden were annotated as clinical improvement, anemia response, spleen response, orsymptoms response. Additional criteria are provided for progressive disease, stable disease, and relapse. The objective response was defined as the number of patients with confirmed "complete remission (CR) + partial response (PR) + clinical improvement (CI)" during the treatment period.
The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Patients can appear in more than one dose-level cohort.
For 300 mg QD, data from 7 patients were available. 4 patients were enrolled originally and 2 patients were dose-reduced from 400 mg QD and 1 patient was dose-reduced from 250 mg BID.
Posted
Count of Participants
Participants
Cycle 7 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Secondary
Part 1: Change From Baseline in Spleen Size
Change from baseline in spleen size was assessed by palpation.
The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Patients can appear in more than one dose-level cohort.
At 200 mg BID cohort, 3 patients were enrolled originally, 2 patients were dose-escalated from 100 mg BID cohort and 8 patients were dose-reduced from 300 mg BID or 400 mg BID cohort.
Posted
Mean
Standard Deviation
cm
From Baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG001
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Secondary
Part 1: Change From Baseline in Bone Marrow Assessment
Bone marrow was assessed by aspiration and biopsy for grade changes in osteomyelofibrosis. Fibrosis was graded according to European Consensus Myelofibrosis Grading Criteria, ranging from grade 0, which corresponds to normal bone marrow, to grade 3, in which coarse bundles of collagen fibrosis are identifiable with significant osteosclerosis.
The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. Here, the overall number of subjects analyzed signifies only the subjects with available data that were analyzed evaluated on that specific cycle day.
Posted
Count of Participants
Participants
From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG001
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Secondary
Part 1: Change From Baseline in Quality of Life Assessments Using Myelofibrosis Symptom Assessment Form (MF-SAF)
MF SAF is a 20-item instrument comprised of 4 subscales: 1) the Brief Fatigue Inventory [= average of 9 fatigue scores], 2) Splenomegaly associated symptoms [= average of 4 splenomegaly and associated scores], 3) Catabolic/proliferative Symptoms [= average of 3 catabolic/proliferative associated scores] and 4) Overall Quality of Life. The items were on a scale from 1 to 10 where 1= most favorable, and 10= least favorable.
The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Patients can appear in more than one dose-level cohort.
For 300 mg QD, data from 7 patients were available. 4 patients were enrolled originally and 2 patients were dose-reduced from 400 mg QD and 1 patient was dose-reduced from 250 mg BID.
Posted
Mean
Standard Deviation
score on a scale
From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG001
Part 1: 125 mg QD
Secondary
Part 2: Change From Baseline in Quality of Life Assessments Using Myeloproliferative Neoplasm Symptom Assessment Form (MPN SAF (MPN 10)
Symptoms are evaluated by the MPN-SAF Total Symptom Score (TSS). The MPN-SAF TSS is assessed by the patients themselves and this includes fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Scoring is from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be) for each item. The MPN-SAF TSS is the summation of all the individual scores (0-100 scale). Symptoms response requires >50% reduction in the MPN-SAF TSS.
The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. Here, the overall number of subjects analyzed signifies only the subjects with available data that were analyzed evaluated on that specific cycle day.
Posted
Mean
Standard Deviation
score on a scale
From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Secondary
Part 1 and Part 2: Change in Baseline in Janus Kinase 2 (JAK2) V617F Allele Burden Levels
The JAK2 V617F allele burden mean changes from baseline (%) are presented as pharmacodynamics parameters.
The PD population included all patients who received at least one dose of study drug and had a baseline and at least one post-baseline PD assessment (for at least one PD parameter). Here, the overall number of subjects analyzed signifies only the subjects with available data that were analyzed evaluated on that specific cycle day.
Posted
Mean
Standard Deviation
Percentage of JAK2 V617F Level
Part 1 and Part 2: From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG001
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Secondary
Part 2: Change From Baseline in Phosphorylated Signal Transducer and Activator of Transcription 3 (Phospho-STAT3)
The Phospho-STAT3 mean changes from baseline (%) are presented as pharmacodynamics parameters.
For phospho-STAT3 values (Phase 2 only), study samples were incubated (± IL-6) and labeled with CD markers. Surface markers included CD3+ (CD4+ [helper T cells] and CD8+ [cytotoxic T cells]) and CD14+ (monocytes) to which intracellular phospho STAT3 was targeted. The levels of phospho-STAT3 in CD14+, CD3+CD4+ and CD3+CD8+ cell subtypes were quantified. Phosphorylated-STAT3 levels were evaluated in the cell types before and after IL-6 incubation (stimulation) and reported both as mean fluorescence intensity (MFI) and the percentage of positive cells. For each sample time point, the MFI was normalized to a fold change.
The fold change was calculated by MFI after IL-6 treatment/MFI before IL-6 treatment. The percent positive cells were normalized by subtracting the percent positive cells before IL-6 treatment from the percent positive cells after IL-6 treatment.
The PD population included all patients who received at least one dose of study drug and had a baseline and at least one post-baseline PD assessment (for at least one PD parameter). Here, number analyzed reflects number of patients evaluated on that specific cycle day.
Data from 17 out of 24 participants were available and contributed to the analysis. Samples from 7 patients were analyzed, but data were not available due to quantities not sufficient.
Posted
Mean
Standard Deviation
Percentage of Phospho-STAT 3 Levels
From Baseline to Pre-dose at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 2: 300 mg QD
Secondary
Part1 and Part 2: Observed Maximum Concentration (Cmax)
To determine the Cmax as pharmacokinetic parameters of NS-018.
The PK population include all patients who received at least one dose of study drug and have at least 50% of the planned samples above the limit of quantitation to provide evaluable PK profile, Here, number analyzed reflects number of patients evaluated on that specific cycle day.
Part 2: 1 patient was completely excluded from PK Population due to critical samples missing, 1 patient was excluded from the analysis due to sample missing at timepoint, So the overall number of participants was 27.
Posted
Mean
Standard Deviation
nanogram/milliliter (ng/mL)
Pre-dose, 0.5 to 24 hours post-dose for Part 1: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1 and for Part 2: Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG001
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Secondary
Part 1 and Part 2: Time to Maximum Plasma Concentration (Tmax)
To determine the Tmax as pharmacokinetic parameters of NS-018.
The PK population include all patients who received at least one dose of study drug and have at least 50% of the planned samples above the limit of quantitation to provide evaluable PK profile, Here, number analyzed reflects number of patients evaluated on that specific cycle day.
Part 2: 1 patient was completely excluded from PK Population due to critical samples missing, 1 patient was excluded from the analysis due to sample missing at timepoint, So the overall number of participants was 27.
Posted
Median
Full Range
hours (h)
Pre-dose, 0.5 to 24 hours post-dose for Part 1: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1 and for Part 2: Cycle 1 Day 1, Cycle 2 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG001
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Secondary
Part1 and Part 2: Area Under the Plasma Concentration-time Curve (AUC0-24)
To determine the AUC0-24 as pharmacokinetic parameters of NS-018.
The PK Population includes all patients who received at least one dose of study drug and have at least 50% of the planned samples above the limit of quantitation to provide evaluable PK profile, regardless of whether derived from parent drug or metabolites.
Part 2: One patient was completely excluded from the PK Population due to critical samples missing; Two patients were excluded from the analysis due to sample missing at time point. so the overall number of participants analyzed was 26.
Posted
Mean
Standard Deviation
hour*nanogram/milliliter (h*ng/mL)
Pre-dose, 0.5 to 24 hours post-dose for Part 1: Cycle 1 Day 1, Cycle 2 Day 1 and for Part 2: Cycle 1 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG001
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Secondary
Part 1 and Part 2: Terminal Elimination Half-life (t½)
To determine the t½ as pharmacokinetic parameters of NS-018.
The PK population include all patients who received at least one dose of study drug and have at least 50% of the planned samples above the limit of quantitation to provide evaluable PK profile, Here, number analyzed reflects number of patients evaluated on that specific cycle day.
Part 2: 1 patient was completely excluded from PK Population due to critical samples missing, 1 patient was excluded from the analysis due to sample missing at timepoint, So the overall number of participants was 27.
Posted
Mean
Standard Deviation
hour (h)
Pre-dose, 0.5 to 24 hours post-dose for Part 1: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1 and for Part 2: Cycle 1 Day 1, Cycle 2 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG001
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Secondary
Part1 and Part 2: Accumulation Ratio (AR)
To determine the AR as pharmacokinetic parameters of NS-018. AR was calculated as AR = (AUC0-24) Cycle 2 Day 1/ (AUC0-24) Cycle 1 Day 1.
The PK Population includes all patients who received at least one dose of study drug and have at least 50% of the planned samples above the limit of quantitation to provide evaluable PK profile (i.e. at least Cmax and AUC evaluable), regardless of whether derived from parent drug or metabolites.
Posted
Mean
Standard Deviation
Ratio
Part 1 and Part 2: Cycle 2 Day 1 (duration of cycle was 4 weeks)
ID
Title
Description
OG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG001
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG002
Part 1: 200 mg QD
Time Frame
Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Description
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
0
3
2
3
3
3
EG001
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
0
4
2
4
4
4
EG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
0
10
2
10
9
10
EG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
0
15
6
15
14
15
EG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
0
4
1
4
4
4
EG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
0
5
1
5
4
5
EG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
0
13
4
13
11
13
EG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
0
8
3
8
8
8
EG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
0
12
4
12
12
12
EG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
0
8
3
8
7
8
EG010
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
1
29
13
29
29
29
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Pneumonia
Infections and infestations
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG0033 affected15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0062 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
Sepsis
Infections and infestations
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Appendicitis perforated
Infections and infestations
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Arthritis infective
Infections and infestations
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Cellulitis
Infections and infestations
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Influenza
Infections and infestations
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Urosepsis
Infections and infestations
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Anaemia
Blood and lymphatic system disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0011 affected4 at risk
EG0020 affected10 at risk
EG003
Thrombocytopenia
Blood and lymphatic system disorders
MedDRA v23.0
Non-systematic Assessment
EG0001 affected3 at risk
EG0011 affected4 at risk
EG0020 affected10 at risk
EG003
Haemolysis
Blood and lymphatic system disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Haemolytic anaemia
Blood and lymphatic system disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Splenic infarction
Blood and lymphatic system disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0021 affected10 at risk
EG003
Splenomegaly
Blood and lymphatic system disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Dizziness
Nervous system disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Hypoaesthesia
Nervous system disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Paraesthesia
Nervous system disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Seizure
Nervous system disorders
MedDRA v23.0
Non-systematic Assessment
EG0001 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Syncope
Nervous system disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0021 affected10 at risk
EG003
Abdominal pain
Gastrointestinal disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0011 affected4 at risk
EG0020 affected10 at risk
EG003
Dysphagia
Gastrointestinal disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Enterocolitis
Gastrointestinal disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Gastrointestinal haemorrhage
Gastrointestinal disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Chronic obstructive pulmonary disease
Respiratory, thoracic and mediastinal disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Epistaxis
Respiratory, thoracic and mediastinal disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Lung infiltration
Respiratory, thoracic and mediastinal disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Pulmonary oedema
Respiratory, thoracic and mediastinal disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Angina pectoris
Cardiac disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Acute coronary syndrome
Cardiac disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Coronary artery occlusion
Cardiac disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Myocardial infarction
Cardiac disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Sinus node dysfunction
Cardiac disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0021 affected10 at risk
EG003
Chest pain
General disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Generalised oedema
General disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Non-cardiac chest pain
General disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Bursitis
Musculoskeletal and connective tissue disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Muscular weakness
Musculoskeletal and connective tissue disorders
MedDRA v23.0
Non-systematic Assessment
EG0001 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Spinal stenosis
Musculoskeletal and connective tissue disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Steroid diabetes
Metabolism and nutrition disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Tumour lysis syndrome
Metabolism and nutrition disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Glioblastoma multiforme
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Lung adenocarcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Bone neoplasm
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Muscle neoplasm
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Neoplasm
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0021 affected10 at risk
EG003
Skin cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Transitional cell carcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Hepatic pain
Hepatobiliary disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Hepatomegaly
Hepatobiliary disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Jaundice
Hepatobiliary disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Weight decreased
Investigations
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Hypoglycaemia
Metabolism and nutrition disorders
MedDRA v23.0
Non-systematic Assessment
EG0000 affected3 at risk
EG0010 affected4 at risk
EG0020 affected10 at risk
EG003
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
This confidential document is the property of NS Pharma, Inc. No unpublished information contained herein may be disclosed without prior written approval from NS Pharma, Inc. Access to this document must be restricted to relevant parties.
Hospitalization or Prolongation of Existing Hospitalization
Title
Measurements
OG0001
OG0012
OG0022
OG0036
OG0041
OG0051
OG0063
OG0072
OG0083
OG0091
OG01011
Death
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG0040
OG0050
OG0060
OG0070
OG0080
OG0090
OG0101
Units
Counts
Participants
OG00012
Title
Denominators
Categories
Title
Measurements
OG0001
16
Title
Denominators
Categories
Title
Measurements
OG000-335918.1± 558459.9
OG000
3
Title
Denominators
Categories
Title
Measurements
Increased by at least 1 grade level
OG0001
Increased by at least 2 grade level
OG0000
Decreased by at least 1 grade level
OG0002
Decreased by at least 2 grade level
OG0000
OG001
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG0000
OG0013
OG0022
OG0037
OG0040
OG0053
OG0063
OG0071
OG0083
OG0090
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0020
OG0032
OG0040
OG0050
OG0061
OG0070
OG0081
OG0090
OG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG0000
OG0013
OG0022
OG0036
OG0040
OG0053
OG00613
OG0071
OG0083
OG0090
Title
Denominators
Categories
Title
Measurements
OG001-0.67± 2.89
OG002-8.25± 3.18
OG003-3.17± 3.97
OG005-3.00± 3.00
OG006-4.33± 6.66
OG007-7.00± NAAs only 1 participant was evaluable, hence SD is not calculable.
OG008-2.00± 3.00
OG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG0000
OG0011
OG0020
OG0034
OG0040
OG0051
OG0060
OG0070
OG0082
OG0090
Title
Denominators
Categories
Title
Measurements
Increased by at least 1 grade level
OG0010
OG0031
OG0051
OG0082
Increased by at least 2 grade level
OG0010
OG0030
OG0050
OG0080
Decreased by at least 1 grade level
OG0011
OG0033
OG0050
OG0080
Decreased by at least 2 grade level
OG0010
OG0030
OG0050
OG0080
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG0000
OG0013
OG0022
OG0037
OG0040
OG0053
OG0062
OG0071
OG0083
OG0090
Title
Denominators
Categories
Brief Fatigue Inventory Score
ParticipantsOG0000
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0037
ParticipantsOG0040
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0071
ParticipantsOG0083
ParticipantsOG0090
Title
Measurements
OG0010.1± 0.4
OG002-1.3± 2.0
OG0030.8± 1.3
OG005
Splenomegaly-associated Symptom Score
ParticipantsOG0000
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0037
Catabolic/Proliferative Symptoms Score
ParticipantsOG0000
ParticipantsOG0012
ParticipantsOG0022
ParticipantsOG0037
Overall Quality of Life Score
ParticipantsOG0000
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0036
Counts
Participants
OG00010
Title
Denominators
Categories
Title
Measurements
OG000-0.7± 3.4
OG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG010
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG0000
OG0011
OG0021
OG0032
OG0040
OG0052
OG0062
OG0072
OG0082
OG0094
OG01011
Title
Denominators
Categories
Title
Measurements
OG0014.360± NAAs only 1 participant was evaluable, hence SD is not calculable.
OG002-0.210± NAAs only 1 participant was evaluable, hence SD is not calculable.
OG0037.410± 2.758
OG005-6.720± 10.479
OG0068.255± 4.320
OG007-4.900± 9.065
OG008-9.033± 5.352
OG009-4.368± 14.602
OG0101.782± 8.978
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG00024
Title
Denominators
Categories
Cycle 1 Day 1: Change percentage of Phospho-STAT3 Levels in CD14+ Positive cells
ParticipantsOG00013
Title
Measurements
OG000-9.406± 19.357
Cycle 1 Day 15: Change percentage of Phospho-STAT3 Levels in CD14+ Positive cells
ParticipantsOG00011
Title
Measurements
OG000-2.738± 16.191
Cycle 2 Day 1: Change percentage of Phospho-STAT3 Levels in CD14+ Positive cells
ParticipantsOG00011
Title
Measurements
OG000-0.422± 20.092
Cycle 1 Day 1: Change percentage of Phospho-STAT3 Levels in CD3+ CD4+ Positive cells
ParticipantsOG00014
Title
Measurements
OG000-10.614± 11.178
Cycle 1 Day 15: Change percentage of Phospho-STAT3 Levels in CD3+ CD4+ Positive cells
ParticipantsOG00012
Title
Measurements
OG0006.217± 20.717
Cycle 2 Day 1: Change percentage of Phospho-STAT3 Levels in CD3+ CD4+ Positive cells
ParticipantsOG00012
Title
Measurements
OG000-5.878± 16.304
Cycle 1 Day 1: Change percentage of Phospho-STAT3 Levels in CD3+ CD8+ Positive cells
ParticipantsOG00014
Title
Measurements
OG000-3.707± 11.222
Cycle 1 Day 15: Change percentage of Phospho-STAT3 Levels in CD3+ CD8+ Positive cells
ParticipantsOG00012
Title
Measurements
OG0005.533± 14.513
Cycle 2 Day 1: Change percentage of Phospho-STAT3 Levels in CD3+ CD8+ Positive cells
ParticipantsOG00012
Title
Measurements
OG000-1.644± 6.615
OG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG010
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0036
OG0043
OG0053
OG0063
OG0076
OG0088
OG0098
OG01027
Title
Denominators
Categories
Cycle 1 Day 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0036
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG0088
ParticipantsOG0098
ParticipantsOG01027
Title
Measurements
OG00066.5600± 79.0171
OG001404.5333± 26.4258
OG002377.8000± 184.2086
OG003
Cycle 1 Day 8 (Part 1 only)
ParticipantsOG0002
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0036
Cycle 1 Day 15 (Part 2 only)
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Cycle 2 Day 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0035
OG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG010
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0036
OG0043
OG0053
OG0063
OG0076
OG0088
OG0098
OG01027
Title
Denominators
Categories
Cycle 1 Day 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0036
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG0088
ParticipantsOG0098
ParticipantsOG01027
Title
Measurements
OG0001.00(0.92 to 2.00)
OG0011.08(1.00 to 2.00)
OG0022.00(1.00 to 2.17)
OG003
Cycle 1 Day 8 (Part 1 only)
ParticipantsOG0002
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0036
Cycle 2 Day 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0035
OG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG010
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0035
OG0043
OG0053
OG0063
OG0074
OG0088
OG0097
OG01026
Title
Denominators
Categories
Cycle 1 Day 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0035
ParticipantsOG0043
ParticipantsOG0052
ParticipantsOG0063
ParticipantsOG0074
ParticipantsOG0088
ParticipantsOG0097
ParticipantsOG01026
Title
Measurements
OG000246.3454± 325.7347
OG0011510.0507± 123.2939
OG0021326.3929± 815.0175
OG003
Cycle 2 Day 1 (Part 1 only)
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0035
OG002
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG007
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG008
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG010
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0036
OG0043
OG0053
OG0063
OG0076
OG0087
OG0097
OG01027
Title
Denominators
Categories
Cycle 1 Day 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0036
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG0087
ParticipantsOG0097
ParticipantsOG01027
Title
Measurements
OG0002.4878± 2.1008
OG0015.1659± 0.5209
OG0023.6685± 2.2953
OG003
Cycle 1 Day 8 (Part 1 only)
ParticipantsOG0002
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0036
Cycle 2 Day 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0035
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG003
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG004
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG005
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG006
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG007
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG008
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG009
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
OG010
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
Units
Counts
Participants
OG0001
OG0013
OG0022
OG0034
OG0043
OG0052
OG0062
OG0073
OG0083
OG0091
OG01022
Title
Denominators
Categories
Title
Measurements
OG0000.9778± NAAs only 1 participant was evaluable, hence SD is not calculable.
OG0011.2517± 0.5579
OG0021.1728± 0.0372
OG0031.3581± 0.3108
OG0041.2026± 0.4755
OG0051.9941± 0.6140
OG0063.3229± 0.3197
OG0073.0501± 2.6306
OG0081.5452± 0.4025
OG0091.2514± NAAs only 1 participant was evaluable, hence SD is not calculable.
OG0101.0543± 0.2572
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
3 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0062 affected13 at risk
EG0073 affected8 at risk
EG0087 affected12 at risk
EG0091 affected8 at risk
EG01010 affected29 at risk
3 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0062 affected13 at risk
EG0073 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0104 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0072 affected8 at risk
EG0082 affected12 at risk
EG0091 affected8 at risk
EG0104 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0108 affected29 at risk
1 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0072 affected8 at risk
EG0085 affected12 at risk
EG0091 affected8 at risk
EG0106 affected29 at risk
3 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0082 affected12 at risk
EG0091 affected8 at risk
EG0101 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0082 affected12 at risk
EG0091 affected8 at risk
EG0102 affected29 at risk
3 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0072 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0041 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0103 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0062 affected13 at risk
EG0070 affected8 at risk
EG0082 affected12 at risk
EG0091 affected8 at risk
EG0103 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0072 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0103 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0103 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0104 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
5 affected
15 at risk
EG0041 affected4 at risk
EG0051 affected5 at risk
EG0064 affected13 at risk
EG0074 affected8 at risk
EG0083 affected12 at risk
EG0092 affected8 at risk
EG0107 affected29 at risk
5 affected
15 at risk
EG0040 affected4 at risk
EG0052 affected5 at risk
EG0062 affected13 at risk
EG0071 affected8 at risk
EG0084 affected12 at risk
EG0092 affected8 at risk
EG01013 affected29 at risk
2 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0106 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
3 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
6 affected
15 at risk
EG0041 affected4 at risk
EG0052 affected5 at risk
EG0063 affected13 at risk
EG0072 affected8 at risk
EG0084 affected12 at risk
EG0092 affected8 at risk
EG01011 affected29 at risk
5 affected
15 at risk
EG0040 affected4 at risk
EG0052 affected5 at risk
EG0061 affected13 at risk
EG0072 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG01010 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0072 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0103 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0062 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0091 affected8 at risk
EG0102 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0072 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0103 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0103 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
3 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0107 affected29 at risk
3 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0061 affected13 at risk
EG0071 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0063 affected13 at risk
EG0071 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0104 affected29 at risk
5 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0062 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0105 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0105 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
5 affected
15 at risk
EG0042 affected4 at risk
EG0052 affected5 at risk
EG0063 affected13 at risk
EG0073 affected8 at risk
EG0086 affected12 at risk
EG0092 affected8 at risk
EG0108 affected29 at risk
4 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0071 affected8 at risk
EG0085 affected12 at risk
EG0091 affected8 at risk
EG01011 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0082 affected12 at risk
EG0092 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0042 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0082 affected12 at risk
EG0092 affected8 at risk
EG0103 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
3 affected
15 at risk
EG0041 affected4 at risk
EG0052 affected5 at risk
EG0065 affected13 at risk
EG0072 affected8 at risk
EG0086 affected12 at risk
EG0093 affected8 at risk
EG01012 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0073 affected8 at risk
EG0083 affected12 at risk
EG0091 affected8 at risk
EG0104 affected29 at risk
1 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0103 affected29 at risk
2 affected
15 at risk
EG0041 affected4 at risk
EG0051 affected5 at risk
EG0064 affected13 at risk
EG0072 affected8 at risk
EG0081 affected12 at risk
EG0091 affected8 at risk
EG0107 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0072 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0061 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0102 affected29 at risk
3 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0062 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0104 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0072 affected8 at risk
EG0081 affected12 at risk
EG0091 affected8 at risk
EG0102 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0101 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0102 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0103 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
5 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0062 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0041 affected4 at risk
EG0051 affected5 at risk
EG0062 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0091 affected8 at risk
EG0101 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0052 affected5 at risk
EG0062 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0103 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0062 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0101 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
3 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0104 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0082 affected12 at risk
EG0091 affected8 at risk
EG0103 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0104 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0062 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0103 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0091 affected8 at risk
EG0102 affected29 at risk
3 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0074 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0104 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0103 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0092 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0062 affected13 at risk
EG0070 affected8 at risk
EG0083 affected12 at risk
EG0090 affected8 at risk
EG0103 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
2 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0082 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0041 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0081 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0091 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0092 affected8 at risk
EG0103 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0091 affected8 at risk
EG0101 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0081 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
1 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0071 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0051 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
3 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0061 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0100 affected29 at risk
0 affected
15 at risk
EG0040 affected4 at risk
EG0050 affected5 at risk
EG0060 affected13 at risk
EG0070 affected8 at risk
EG0080 affected12 at risk
EG0090 affected8 at risk
EG0102 affected29 at risk
1
BG0052
BG0063
BG0075
BG0082
BG0095
BG01015
BG01144
0
BG0040
BG0050
BG0061
BG0070
BG0080
BG0090
BG0101
BG0113
0
BG0041
BG0050
BG0060
BG0070
BG0080
BG0090
BG0101
BG0112
0
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
BG0101
BG0111
-1.9
± 0.1
OG0060.4± 0.2
OG0070.7± NAAs only 1 participant was evaluable, hence SD is not calculable.
OG008-0.8± 1.1
ParticipantsOG0040
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0071
ParticipantsOG0083
ParticipantsOG0090
Title
Measurements
OG0011.3± 1.3
OG002-0.5± 1.1
OG0030.5± 0.8
OG005-0.3± 1.8
OG006-1.1± 1.2
OG007-4.0± NAAs only 1 participant was evaluable, hence SD is not calculable.
OG008-1.8± 1.5
ParticipantsOG0040
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0071
ParticipantsOG0083
ParticipantsOG0090
Title
Measurements
OG0011.2± 0.2
OG002-0.7± 0.5
OG003-0.4± 2.4
OG005-0.4± 1.0
OG0061.5± 1.6
OG007-8.0± NAAs only 1 participant was evaluable, hence SD is not calculable.
OG008-0.6± 1.0
ParticipantsOG0040
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0071
ParticipantsOG0083
ParticipantsOG0090
Title
Measurements
OG0010.3± 0.6
OG002-1.0± 1.4
OG0030.0± 3.6
OG005-1.7± 2.1
OG006-1.5± 2.1
OG0070.0± NAAs only 1 participant was evaluable, hence SD is not calculable.
OG008-1.7± 1.5
726.0667
± 232.0338
OG0041643.0333± 789.0036
OG005242.0333± 174.3374
OG006351.0000± 257.1729
OG007853.5833± 271.7900
OG0081077.4750± 366.9158
OG0091261.7000± 658.9141
OG010957.9852± 306.7937
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG0086
ParticipantsOG0095
ParticipantsOG0100
Title
Measurements
OG00030.6700± 13.3077
OG001324.8667± 57.3280
OG002539.6667± 160.0954
OG003805.4333± 236.8877
OG0041554.6667± 351.6765
OG005412.8000± 232.9342
OG006606.8333± 233.7812
OG007806.8333± 464.3206
OG008969.0167± 342.3090
OG0091352.2200± 307.1358
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG01024
Title
Measurements
OG010732.5000± 313.5822
Participants
OG004
3
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0073
ParticipantsOG0085
ParticipantsOG0092
ParticipantsOG01023
Title
Measurements
OG00067.6467± 55.6250
OG001450.6667± 187.4735
OG002556.9000± 52.8463
OG0031066.0000± 271.1854
OG0041556.0000± 676.3941
OG005408.6000± 127.0765
OG006596.1333± 362.6751
OG007830.7333± 166.0701
OG0081272.5600± 420.7722
OG0091040.6500± 321.5215
OG0101035.3087± 445.9895
1.04
(1.00 to 2.00)
OG0041.00(1.00 to 2.00)
OG0051.00(1.00 to 1.08)
OG0061.00(1.00 to 1.00)
OG0071.46(1.00 to 2.13)
OG0081.02(1.00 to 23.58)
OG0092.00(1.00 to 6.00)
OG0102.00(0.92 to 3.00)
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG0086
ParticipantsOG0095
ParticipantsOG0100
Title
Measurements
OG0000.78(0.50 to 1.05)
OG0011.00(1.00 to 1.12)
OG0021.00(1.00 to 2.00)
OG0031.54(1.02 to 2.25)
OG0042.00(1.00 to 2.05)
OG0051.00(0.50 to 1.08)
OG0061.00(0.50 to 1.02)
OG0071.98(1.00 to 3.00)
OG0081.52(0.83 to 4.42)
OG0092.03(2.00 to 4.00)
Participants
OG004
3
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0073
ParticipantsOG0085
ParticipantsOG0092
ParticipantsOG01023
Title
Measurements
OG0001.00(1.00 to 2.05)
OG0011.00(1.00 to 2.03)
OG0021.00(1.00 to 1.00)
OG0031.05(0.83 to 2.00)
OG0041.00(0.82 to 1.02)
OG0051.00(0.53 to 1.00)
OG0061.00(1.00 to 2.08)
OG0072.07(1.00 to 4.00)
OG0082.08(1.00 to 5.53)
OG0092.00(1.00 to 3.00)
OG0101.08(0.92 to 3.00)
2299.2216
± 877.2554
OG0045162.4119± 2485.9489
OG0051022.0977± 521.6626
OG0061241.5005± 461.6010
OG0072117.1396± 449.2456
OG0085666.7063± 5182.5571
OG0097592.4070± 3031.4332
OG0103672.2041± 1551.7435
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0073
ParticipantsOG0084
ParticipantsOG0091
ParticipantsOG0100
Title
Measurements
OG000253.6953± 306.7728
OG0011905.2058± 938.2984
OG0021816.8251± 559.9071
OG0033175.6938± 794.6091
OG0045443.2874± 986.8497
OG0051561.1245± 621.5414
OG0063470.6269± 2587.3663
OG0075876.1106± 5133.4208
OG0086132.2596± 3393.0644
OG0093828.0995± NAAs only 1 participant was evaluable, hence SD is not calculable.